An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...

California pension fund CalPERS, the second-largest public purchaser of health benefits in the U.S., announced on Tuesday ...

The company will offer a generic version of semaglutide in the country after Novo Nordisk let its patent expire there. Hims & ...

Novo Nordisk reportedly failed to pay its annual fees to maintain the patent rights in Canada, opening the door to cheaper ...

Hims & Hers (HIMS) stock in focus as the company faces a growing number of lawsuits following Novo Nordisk's (NVO) decision ...

In an echo of the pattern laid last year, following a record-high outlay at the very beginning of the year, TV drug ad ...

Digging Into the Bargain Bin Investing in beaten-down stocks can be a savvy strategy for long-term wealth creation, as it ...

Will hydrogen airplanes be our future? The first hydrogen planes are already taking flight, and advancements in this ...

In this video, we explore Sienna Mae's embarrassing dance video set to a Sam Smith song in response to Jack Wright, alongside ...

ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...